{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:36:51Z","timestamp":1785832611112,"version":"3.56.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["21-003187"],"award-info":[{"award-number":["21-003187"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.mayocp.2025.11.019","type":"journal-article","created":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:30:06Z","timestamp":1772742606000},"page":"582-591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cancer Incidence and Risk Factors in PLA2R-Associated Membranous Nephropathy"],"prefix":"10.1016","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6151-9336","authenticated-orcid":false,"given":"Ilario","family":"Russo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Vargas-Brochero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anila","family":"Cara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Annese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loreto","family":"Gesualdo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando C.","family":"Fervenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ladan","family":"Zand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2025.11.019_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-021-00303-z","article-title":"Membranous nephropathy","volume":"7","author":"Ronco","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.mayocp.2025.11.019_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000364782","article-title":"Prevalence of cancer in membranous nephropathy: a systematic review and meta-analysis of observational studies","volume":"40","author":"Leeaphorn","year":"2014","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1016\/j.mayocp.2025.11.019_bib3","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.kint.2023.06.032","article-title":"Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification","volume":"104","author":"Sethi","year":"2023","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.mayocp.2025.11.019_bib4","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.mayocp.2020.11.028","article-title":"A target antigen-based approach to the classification of membranous nephropathy","volume":"96","author":"Bobart","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mayocp.2025.11.019_bib5","article-title":"Specific antigens in malignancy-associated membranous nephropathy. Mini review","volume":"11","author":"Hu","year":"2024","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.mayocp.2025.11.019_bib6","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ajkd.2007.06.003","article-title":"Long-term risk of cancer in membranous nephropathy patients","volume":"50","author":"Bjorneklett","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2025.11.019_bib7","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.2215\/CJN.08880813","article-title":"Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy","volume":"9","author":"van den Brand","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2025.11.019_bib8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1159\/000481635","article-title":"Membranous nephropathy: approaches to treatment","volume":"47","author":"Bomback","year":"2018","journal-title":"Am J Nephrol"},{"issue":"12","key":"10.1016\/j.mayocp.2025.11.019_bib9","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1093\/ndt\/gfu387","article-title":"Onco-nephrology: an appraisal of the cancer and chronic kidney disease links","volume":"30","author":"Izzedine","year":"2015","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.mayocp.2025.11.019_bib10","doi-asserted-by":"crossref","first-page":"530","DOI":"10.2215\/CJN.10820918","article-title":"Estimated glomerular filtration rate and the risk of cancer","volume":"14","author":"Xu","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"10","key":"10.1016\/j.mayocp.2025.11.019_bib11","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1681\/ASN.2013060604","article-title":"CKD and the risk of incident cancer","volume":"25","author":"Lowrance","year":"2014","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1016\/j.mayocp.2025.11.019_bib12","doi-asserted-by":"crossref","first-page":"6429","DOI":"10.7150\/jca.47175","article-title":"Association between kidney function and the risk of cancer: results from the China Health and Retirement longitudinal study (CHARLS)","volume":"11","author":"Liu","year":"2020","journal-title":"J Cancer"},{"issue":"5","key":"10.1016\/j.mayocp.2025.11.019_bib13","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1681\/ASN.2007060712","article-title":"Association of albuminuria and cancer incidence","volume":"19","author":"J\u00f8rgensen","year":"2008","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.mayocp.2025.11.019_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.ajkd.2017.03.018","article-title":"Kidney function, proteinuria, and cancer incidence: the Korean Heart Study","volume":"70","author":"Mok","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.mayocp.2025.11.019_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/nrc1675","article-title":"Cancer and ageing: a nexus at several levels","volume":"5","author":"Balducci","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.mayocp.2025.11.019_bib18","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1146\/annurev-physiol-030212-183653","article-title":"Aging, cellular senescence, and cancer","volume":"75","author":"Campisi","year":"2013","journal-title":"Annu Rev Physiol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.11.019_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cger.2011.09.001","article-title":"Cancer and age: general considerations","volume":"28","author":"Hoffe","year":"2012","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"10.1016\/j.mayocp.2025.11.019_bib20","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0025-7125(16)30355-8","article-title":"The health consequences of smoking. Cancer","volume":"76","author":"Newcomb","year":"1992","journal-title":"Med Clin North Am"},{"issue":"6","key":"10.1016\/j.mayocp.2025.11.019_bib21","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1001\/jamaoncol.2017.3605","article-title":"Prevalence of prior cancer among persons newly diagnosed with cancer: an initial report from the Surveillance, Epidemiology, and End Results Program","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.mayocp.2025.11.019_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7069","article-title":"Personal history of cancer as a risk factor for second primary lung cancer: implications for lung cancer screening","volume":"13","author":"Nofal","year":"2024","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.mayocp.2025.11.019_bib23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13075-024-03285-x","article-title":"Evaluating the safety profile of calcineurin inhibitors: cancer risk in patients with systemic lupus erythematosus from the LUNA registry\u2014a historical cohort study","volume":"26","author":"Ichinose","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.mayocp.2025.11.019_bib24","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3389\/fimmu.2019.01990","article-title":"Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders","volume":"10","author":"Kaegi","year":"2019","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.mayocp.2025.11.019_bib25","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.mayocp.2025.11.019_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100853","article-title":"Obinutuzumab in refractory membranous nephropathy: a case series","volume":"6","author":"Lin","year":"2024","journal-title":"Kidney Med"},{"issue":"3","key":"10.1016\/j.mayocp.2025.11.019_bib27","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2024","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1016\/j.mayocp.2025.11.019_bib28","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1681\/ASN.2008090998","article-title":"Association of CKD and cancer risk in older people","volume":"20","author":"Wong","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2025.11.019_bib29","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1006\/abbi.1999.1511","article-title":"Biological and pathological functions of phospholipase A2 receptor","volume":"372","author":"Hanasaki","year":"1999","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.mayocp.2025.11.019_bib30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.semcancer.2017.11.002","article-title":"Current insights into functions of phospholipase A2 receptor in normal and cancer cells: more questions than answers","volume":"56","author":"Sukocheva","year":"2019","journal-title":"Semin Cancer Biol"},{"issue":"38","key":"10.1016\/j.mayocp.2025.11.019_bib31","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1038\/onc.2016.43","article-title":"The PLA2R1-JAK2 pathway upregulates ERR\u03b1 and its mitochondrial program to exert tumor-suppressive action","volume":"35","author":"Griveau","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.mayocp.2025.11.019_bib32","first-page":"40","article-title":"PLA2R1: expression and function in cancer","volume":"1846","author":"Bernard","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.mayocp.2025.11.019_bib33","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.freeradbiomed.2013.08.177","article-title":"PLA2R1 kills cancer cells by inducing mitochondrial stress","volume":"65","author":"Augert","year":"2013","journal-title":"Free Radic Biol Med"},{"issue":"6","key":"10.1016\/j.mayocp.2025.11.019_bib34","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/ndt\/gfad261","article-title":"Are patients with primary glomerular disease at increased risk of malignancy?","volume":"39","author":"Han","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.mayocp.2025.11.019_bib35","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12882-018-0828-2","article-title":"Quantification of cancer risk in glomerulonephritis","volume":"19","author":"Heaf","year":"2018","journal-title":"BMC Nephrol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625181603?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619625181603?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:12:13Z","timestamp":1779307933000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619625181603"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0025619625181603"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.11.019","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer Incidence and Risk Factors in PLA2R-Associated Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2025.11.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}